First participant enrolled in the HVTN318 clinical trial evaluating the safety and immunogenicity of an innovative French vaccine candidate, CD40.HIVRI.Env

 

Paris, September 12th 2025

 

PRESS RELEASE

 

Developing a preventive vaccine against HIV infection (human immunodeficiency virus) remains a major priority in effectively combating virus transmission. The Vaccine Research Institute (VRI) has developed an innovative vaccine candidate, CD40.HIVRI.Env, which showed promising results in the ANRS VRI06 clinical trial (NCT04842682; Levy Y et al., 2024, eClinical Medicine).

 

This vaccine candidate is now entering a new phase of evaluation within the HVTN318 clinical trial (NCT06665646), sponsored by the NIAID, as part of the HVTN network. The study is being conducted at seven clinical sites across the United States. The primary objective of this trial is to assess the safety and immunogenicity of the CD40.HIVRI.Env vaccine, adjuvanted with poly-ICLC (Hiltonol), in volunteers who previously participated in the HVTN706 clinical trial.

The first participant has just been enrolled for this study, which plans to enroll a total of 40 volunteers from the HVTN706 study.

 

Press contact : ANRS MIE
presse@anrs.fr